These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28189403)

  • 21. Lessons Learned From the Introduction of Inactivated Poliovirus Vaccine in Bangladesh.
    Estivariz CF; Snider CJ; Anand A; Hampton LM; Bari TI; Billah MM; Chai SJ; Wassilak SG; Heffelfinger JD; Zaman K
    J Infect Dis; 2017 Jul; 216(suppl_1):S122-S129. PubMed ID: 28838154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fractional dose compared with standard dose inactivated poliovirus vaccine in children: a systematic review and meta-analysis.
    Mashunye TR; Ndwandwe DE; Dube KR; Shey M; Shelton M; Wiysonge CS
    Lancet Infect Dis; 2021 Aug; 21(8):1161-1174. PubMed ID: 33939958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model.
    Norton EB; Bauer DL; Weldon WC; Oberste MS; Lawson LB; Clements JD
    Vaccine; 2015 Apr; 33(16):1909-15. PubMed ID: 25765967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An experience of mass administration of fractional dose inactivated polio vaccine through intradermal needle-free injectors in Karachi, Sindh, Pakistan.
    Bullo UF; Mehraj J; Raza SM; Rasool S; Ansari NN; Shaikh AA; Phul ZA; Memon SA; Baloch RI; Baloch ZA; Chandio SA
    BMC Public Health; 2021 Jan; 21(1):44. PubMed ID: 33407294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increasing vaccine supply with low dead-volume syringes and needles.
    Le Daré B; Bacle A; Lhermitte R; Lesourd F; Lurton Y
    Int J Pharm; 2021 Oct; 608():121053. PubMed ID: 34461171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fractional doses of inactivated poliovirus vaccine in Oman.
    Mohammed AJ; AlAwaidy S; Bawikar S; Kurup PJ; Elamir E; Shaban MM; Sharif SM; van der Avoort HG; Pallansch MA; Malankar P; Burton A; Sreevatsava M; Sutter RW
    N Engl J Med; 2010 Jun; 362(25):2351-9. PubMed ID: 20573923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization.
    Khan MM; Sharma S; Tripathi B; Alvarez FP
    Public Health; 2017 Jan; 142():31-38. PubMed ID: 28057194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protocol for a systematic review and meta-analysis of fractional dose compared with standard dose inactivated polio vaccination in children.
    Mashunye TR; Ndwandwe DE; Dube KR; Shey M; Shelton M; Wiysonge CS
    BMJ Open; 2019 Mar; 9(3):e023308. PubMed ID: 30852530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-sparing effect of Sabin-derived inactivated polio vaccine produced in Japan by intradermal injection device for rats.
    Itoh E; Shimizu S; Ami Y; Iwase Y; Someya Y
    Biologicals; 2023 May; 82():101677. PubMed ID: 37031619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats.
    Ma L; Cai W; Sun M; Cun Y; Zhou J; Liu J; Hu W; Zhang X; Song S; Jiang S; Liao G
    Hum Vaccin Immunother; 2016 Dec; 12(12):3125-3131. PubMed ID: 27558963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remarks on the possibility of introducing the fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule.
    Arbo A; Falleiros-Arlant LH; López EL; Brea Del Castillo J; Martínez de Cuellar C; Moreno G; Rolón R; Cerda J; Eguiazú S;
    Rev Chilena Infectol; 2019 Feb; 36(1):83-90. PubMed ID: 31095207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba.
    Resik S; Tejeda A; Lago PM; Diaz M; Carmenates A; Sarmiento L; Alemañi N; Galindo B; Burton A; Friede M; Landaverde M; Sutter RW
    J Infect Dis; 2010 May; 201(9):1344-52. PubMed ID: 20350164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis.
    Grassly NC
    J Infect Dis; 2014 Nov; 210 Suppl 1(Suppl 1):S439-46. PubMed ID: 24634499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeated fractional intradermal dosing of an inactivated polio vaccine by a single hollow microneedle leads to superior immune responses.
    Schipper P; van der Maaden K; Romeijn S; Oomens C; Kersten G; Jiskoot W; Bouwstra J
    J Control Release; 2016 Nov; 242():141-147. PubMed ID: 27496634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Priming after a fractional dose of inactivated poliovirus vaccine.
    Resik S; Tejeda A; Sutter RW; Diaz M; Sarmiento L; Alemañi N; Garcia G; Fonseca M; Hung LH; Kahn AL; Burton A; Landaverde JM; Aylward RB
    N Engl J Med; 2013 Jan; 368(5):416-24. PubMed ID: 23363495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of SoloShot autodestruct syringes compared with disposable syringes, in a national immunization campaign in Indonesia.
    Nelson CM; Sutanto A; Suradana IG
    Bull World Health Organ; 1999; 77(1):29-33. PubMed ID: 10063658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a study with polio vaccine in rats.
    van der Maaden K; Trietsch SJ; Kraan H; Varypataki EM; Romeijn S; Zwier R; van der Linden HJ; Kersten G; Hankemeier T; Jiskoot W; Bouwstra J
    Pharm Res; 2014 Jul; 31(7):1846-54. PubMed ID: 24469907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
    Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
    Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pandemic influenza preparedness: the critical role of the syringe.
    Strauss K; van Zundert A; Frid A; Costigliola V
    Vaccine; 2006 May; 24(22):4874-82. PubMed ID: 16647790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.